EX-99.SECTION19(A) 3 tm213429d1_ex99section19a.htm EXHIBIT 99.SECTION19(A)

 

Exhibit 99.Section 19(a)

 

EXHIBIT 3: SECTION 19(a) NOTICE TO FUND’S SHAREHOLDERS

 

TEKLA LIFE SCIENCES INVESTORS

 

Notification of Sources of Distribution

 

Distribution Paid Date:   December 31, 2020

 

Distribution Amount Per Common Share:   $0.40

 

The following table sets forth the estimated amounts of the current distribution, paid December 31, 2020, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. All amounts are expressed per common share.

 

               Percentage 
       Percentage       Breakdown of the 
       Breakdown   Total Cumulative   Total Cumulative 
   Current   of Current   Distributions for the   Distributions for the 
   Distribution   Distribution   Fiscal Year to Date1   Fiscal Year to Date1 
Net Investment Income  $0.0000    0%  $0.0000    0%
Net Realized ST Cap Gains  $0.3900    98%  $0.3900    98%
Net Realized LT Cap Gains  $0.0100    2%  $0.0100    2%
Return of Capital or Other Capital Source  $0.0000    0%  $0.0000    0%
TOTAL (per common share):  $0.4000    100%  $0.4000    100%

 

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

 

Average annual total return at NAV for the period from October 31, 2015 through October 31, 2020   4.97%
Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2020   8.21%
Cumulative total return at NAV for the fiscal year, through October 31, 20202   -3.07%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of October 31, 20201   2.05%

 

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

 

The composition of this and subsequent distribution may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $180,403,667, of which $177,263,254 represents net unrealized appreciation of portfolio securities.

 

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

 

1The Fund’s current fiscal year began on October 1, 2020.

2Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2020 through October 31, 2020.

 

Tekla Life Sciences Investors

CUSIP: 87911K100

www.teklacap.com

 

Tekla Capital Management LLC

100 Federal Street, 19th Floor

Boston, Massachusetts 02110

 

617-772-8500

Fax: 617-772-8577

 

03D6DB 002CSNB5ED

 

 

 

TEKLA LIFE SCIENCES INVESTORS

 

Notification of Sources of Distribution

 

Distribution Paid Date:   January 6, 2021

 

Distribution Amount Per Common Share:   $0.02

 

The following table sets forth the estimated amounts of the current distribution, paid January 6, 2021, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. All amounts are expressed per common share.

 
               Percentage 
       Percentage       Breakdown of the 
       Breakdown   Total Cumulative   Total Cumulative 
   Current   of Current   Distributions for the   Distributions for the 
   Distribution   Distribution   Fiscal Year to Date1   Fiscal Year to Date1 
Net Investment Income  $0.0000    0%  $0.0000    0%
Net Realized ST Cap Gains  $0.0000    0%  $0.3900    93%
Net Realized LT Cap Gains  $0.0200    100%  $0.0300    7%
Return of Capital or Other Capital Source  $0.0000    0%  $0.0000    0%
TOTAL (per common share):  $0.0200    100%  $0.4200    100%

 

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

 

Average annual total return at NAV for the period from November 30, 2015 through November 30, 2020   6.17%
Annualized current distribution rate expressed as a percentage of NAV as of November 30, 20203   0.10%
Cumulative total return at NAV for the fiscal year, through November 30, 20202   4.46%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of November 30, 20201   2.03%

 

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

 

The composition of this and subsequent distribution may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $166,957,956, of which $162,923,941 represents net unrealized appreciation of portfolio securities.

 

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

 

1The Fund’s current fiscal year began on October 1, 2020.

2Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2020 through November 30, 2020.

3 This distribution represents a one time payment to satisfy annual tax distribution requirements and therefore has not been annualized for the period.

 

Tekla Life Sciences Investors

CUSIP: 87911K100

www.teklacap.com

 

Tekla Capital Management LLC

100 Federal Street, 19th Floor

Boston, Massachusetts 02110

 

617-772-8500

Fax: 617-772-8577

 

03D9UB 002CSNB71B

 

 

 

TEKLA LIFE SCIENCES INVESTORS

 

Notification of Sources of Distribution

 

Distribution Paid Date:   March 31, 2021

 

Distribution Amount Per Common Share:   $0.43

 

The following table sets forth the estimated amounts of the current distribution, paid March 31, 2021, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. All amounts are expressed per common share.

 

               Percentage 
       Percentage       Breakdown of the 
       Breakdown   Total Cumulative   Total Cumulative 
   Current   of Current   Distributions for the   Distributions for the 
   Distribution   Distribution   Fiscal Year to Date1   Fiscal Year to Date1 
Net Investment Income  $0.0000    0%  $0.0000    0%
Net Realized ST Cap Gains  $0.0243    6%  $0.4143    49%
Net Realized LT Cap Gains  $0.4057    94%  $0.4357    51%
Return of Capital or Other Capital Source  $0.0000    0%  $0.0000    0%
TOTAL (per common share):  $0.4300    100%  $0.8500    100%

 

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

 

Average annual total return at NAV for the period from January 31, 2016 through January 31, 2021   13.24%
Annualized current distribution rate expressed as a percentage of NAV as of January 31, 2021   7.62%
Cumulative total return at NAV for the fiscal year, through January 31, 20212   13.80%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of January 31, 20211   3.77%

 

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

 

The composition of this and subsequent distribution may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $178,869,122, of which $149,788,813 represents net unrealized appreciation of portfolio securities.

 

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

 

1The Fund’s current fiscal year began on October 1, 2020.

2Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2020 through January 31, 2021.

 

Tekla Life Sciences Investors

CUSIP: 87911K100

www.teklacap.com

 

Tekla Capital Management LLC

100 Federal Street, 19th Floor

Boston, Massachusetts 02110

 

617-772-8500

Fax: 617-772-8577

 

03FMAB 002CSNB9CD